This Review outlines the understanding and management of triple-negative breast cancer
(TNBC). TNBC shares morphological and genetic abnormalities with basal-like breast�…

Breast cancer comprises a heterogeneous group of diseases that vary in morphology,
biology, behaviour and response to therapy. Triple-negative (TN) breast cancer is a subtype�…

The basal molecular subtype of breast cancer (BC) is defined by the mRNA expression
pattern of an intrinsic∼ 500‐gene set. It is the most homogeneous subtype in transcriptional�…

Abstract Purpose: Triple-negative (TN; estrogen receptor, progesterone receptor, and HER-2
negative) cancer and basal-like breast cancer (BLBC) are associated with poor outcome�…

Metastatic cases of breast cancer pose the primary challenge in clinical management of this
disease, demanding the identification of effective therapeutic strategies that remain wanting�…

Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different
orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15�…

The clinical management of triple negative breast cancer (TNBC) is challenging due to the
relatively aggressive biological behaviour and paucity of specific targeted therapy. A subset�…

Triple‐negative breast cancers (TNBCs) are aggressive tumors with poor prognosis
compared to other breast cancer subtypes. The evidence linking TNBC with the metabolic�…

Context.—Advances in the understanding of the molecular and genetic mechanisms of
breast cancer have led to realization of the heterogeneity of the disease and the promise of�…

Molecular stratification of these prognostic groups has been critical in identifying novel
therapeutic targets for future drug development. The development of poly-(ADP) ribose�…